Gaudium IVF & Women Health Ltd.
93.95
INR
-1.05
(-1.11%)
ISIN
INE0P8B01020
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Manika Khanna
- Full Time Employees
- 120
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- New Delhi India
- Website
- gaudiumivfcentre.com
- Similar Companies
- Business
- Gaudium IVF & Women Health Limited provides specialized fertility, reproductive medicine, and comprehensive women's healthcare services across India. Founded in 2009 and headquartered in New Delhi, India, the company operates an asset-light hub-and-spoke clinical network comprising central hub centres located in major metropolitan areas, including Delhi NCR, Mumbai, Bengaluru, and Patna, supported by regional spoke clinics across multiple states to serve patients seeking assisted conception and advanced gynaecological care. The company's core service offerings encompass assisted reproductive technology (ART) procedures, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), laser-assisted hatching, and controlled ovarian stimulation; fertility preservation services, including oocyte and embryo cryopreservation, semen banking, and frozen embryo transfers (FET); male infertility treatments, such as testicular sperm aspiration (TESA), percutaneous epididymal sperm aspiration (PESA), and micro-surgical testicular sperm extraction (micro-TESE); specialized diagnostic and genetic testing services, including pre-implantation genetic testing for aneuploidies and monogenic defects (PGT-A and PGT-M), blastocyst culture, endometrial receptivity assays, and routine reproductive pathology; and minimally invasive surgical and gynaecological care, covering operative laparoscopy, hysteroscopy, tubal recanalization, and clinical management for polycystic ovary syndrome (PCOS/PCOD), endometriosis, uterine fibroids, and recurrent pregnancy loss. The company also dispenses fertility medications, specialized therapeutics, and maternal healthcare products through in-house pharmacy operations managed by its Gaudium International subsidiary. In recent corporate developments, Gaudium IVF & Women Health Limited completed its initial public offering (IPO) in February 2026, raising 1.65 billion Indian rupees through a fresh issue and offer for sale, subsequently listing its equity shares on the National Stock Exchange of India and the BSE. The company is deploying the IPO proceeds to execute a major geographic expansion plan to establish new fertility centres across tier-1 and tier-2 Indian cities, prepay outstanding debt obligations, and support general corporate initiatives. Furthermore, the company has broadened its business scope into the maternal-child wellness and consumer healthcare segments through capital investments in its wholly owned subsidiary, EKK Global Private Limited, to develop and market nutritional supplements and specialized mother-and-baby fast-moving consumer goods.